Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Pharmaceuticals is Selling Off Today -- But Why?

By Brian Feroldi - Dec 7, 2015 at 1:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite releasing positive clinical data the stock still manages to sell off.

What: Shares of Alnylam Pharmaceuticals (ALNY -2.20%) were trading nearly 10% lower at 10:00 a.m. Monday after the company presented updated clinical data on two of its investigational compounds at the ongoing American Society of Hematology meeting.

So what: On Sunday the company gave an update on its ongoing Phase 1/2 trial of ALN-CC5, a compound being tested as a potential treatment for Paroxysmal Nocturnal Hemoglobinuria, or PNH. The results of the trial showed that ALN-CC5 achieved up to a 99% knockdown of Serum C5 levels and up to a 98% inhibition of Serum Hemolytic activity.

Those results managed to meet the company's goal of an 80% reduction in serum hemolytic activity and Alnylam management team believes that ALN-CC5 showed enough durability to possibly support a monthly, or even quarterly, dose regimen. The company will be transitioning the study to include patients with PNH by the end of this year and it plans on providing updated clinical data from this study by mid-2016.

In a second release Alnylam provided a clinical update on ALN-AT3, its potential treatment for Hemophilia. ALN-AT3 has officially been renamed Fitusiran and in its ongoing phase 1 clinical study was able to lower antithrombin activity by up to 88%, which in turn reduced annualized bleeding rates in patients by 85%. Fitusiran was also well tolerated in patients with no serious adverse events reported. Alnylam confirmed that Fitusiran is still on track to initiate phase 3 studies by the middle of next year.

On Dec. 10 Alnylam will be hosting a research and development day that should give its investors more color on the progress that is being made in the company's vast pipeline.

Now what: Overall the clinical data looked good so I'm a bit puzzled why shares are trading lower on Monday. Its possible that the stock is simply selling off because the biotech sector in general is under pressure today. The First Trust NYSE Arca Biotech ETF (FBT -1.62%), an exchange traded fund that invests in an assortment of biotech stocks is also trading much lower today.

Alnylam is still in money-losing mode so its stock is likely to remain subject to the whims of more speculative biotech investors until it shows that it can generate a profit from operations. Until that happens long-term investors should ignore short-term price movements and keep their eyes focused on the clinical data. If Alnylam continues to report good results then the share price will take care of itself.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$223.13 (-2.20%) $-5.02
First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund Stock Quote
First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund
$145.46 (-1.62%) $-2.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.